About Us

Novoviah, established in 2020, specializes in developing ultra-sensitive T cell monitoring systems.

Our flagship technology, the Novoleukin platform, measures T cell reactivity in fresh whole blood to detect antigen-specific T cells.

Novoviah’s platform combines expertise in antigen chemistry, T cell biology, pre-analytics, clinical trial management and translational immunology to deliver functional T cell tests designed for easy clinical site use.

The Novoluekin Test System makes monitoring for rare antigen-specific T cells easy and sensitive for a range of applications:

• clinical research and development
• pharmaceutical and vaccine clinical trials
• companion diagnostics or stand-alone diagnostics for T cell-mediated disease or adverse effects

Expertise to support your program needs

Novoleukin

Ultra-sensitive T cell testing platform for disease detection and monitoring

Novogluten

Standardized gluten product for use in clinical trial challenges

Novofind

Drug discovery platform for T cell-mediated conditions

Opportunities for improved care

Our technology allows for non-invasive, accurate detection of immune-mediated conditions, with applications in studying autoimmunity, infections, and cancers.

Novoviah’s goal is to expand pharmaceutical program support and explore broader applications in clinical care for faster, more accessible diagnosis.

Revolutionizing diagnostic & monitoring tools

Novoviah is built on more than two decades of experience from its founders in the discovery and commercialization of diagnostics and therapeutics, particularly for celiac disease and other immune disorders. With this extensive background, the founders are dedicated to revolutionizing diagnostic and monitoring tools, which in turn will accelerate pharmaceutical development, introduce a new class of diagnostics, and enable personalized treatment approaches for patients.

Clinically proven and globally trusted

Novoviah, working with its clinical collaborators, has extensive experience of the Novoleukin Test System in celiac disease.

Spanning over 100 sites across multiple contients, Novoleukin-C is enabling trials of investigational immune therapies for celiac disease in North America, Europe and Australasia.